Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

被引：3

作者：

Powles, Thomas

Albiges, Laurence

Jalkanen, Katriina Johanna

De Velasco, Guillermo

Burotto, Mauricio

Ghatalia, Pooja

Suarez, Cristina

Lam, Elaine T.

Iacovelli, Roberto

Gumus, Mahmut

Verzoni, Elena

Kollmannsberger, Christian K.

Stadler, Walter Michael

Venugopal, Balaji

Shinde, Reshma

Saretsky, Todd L.

He, Li

Vickery, Donna

Choueiri, Toni K.

Rini, Brian I.

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England

[2] Univ Paris Saclay, Gustave Roussy, Paris, France

[3] Helsinki Univ Hosp, Helsinki, Finland

[4] 12 Octubre Univ Hosp, Med Oncol Dept, Madrid, Spain

[5] Bradford Hill Clin Res Ctr, Santiago, Chile

[6] Fox Chase Canc Ctr, Philadelphia, PA USA

[7] Hosp Univ Vall dHebron, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[8] Univ Colorado, Canc Ctr, Aurora, CO USA

[9] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

[10] Istanbul Medeniyet Univ, Goztepe Prof Dr Suleyman Yalcin City Hosp, Istanbul, Turkiye

[11] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[12] BC Canc Vancouver Canc Ctr, Vancouver, BC, Canada

[13] Univ Chicago, Chicago, IL USA

[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland

[15] Merck & Co Inc, Rahway, NJ USA

[16] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

[17] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.4_suppl.361

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

361

引用

页码：361 / 361

页数：1

共 50 条

[41] Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
Powles, T. B.
Escudier, B.
de Souza, P.
Chowdhury, S.
Pook, D.
Harmenberg, U.
Basappa, N.
Geynisman, D.
Merchan, J.
Redman, B. G.
Ryan, C.
Goodman, O.
Ho, T.
Singh, P.
Lougheed, J.
Patel, M.
Knox, J. J.
Motzer, R. J.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2016, 27
[42] CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
Sharma, P.
Escudier, B.
McDermott, D. F.
George, S.
Hammers, H. J.
Srinivas, S.
Tykodi, S. S.
Sosman, J. A.
Procopio, G.
Plimack, E. R.
Castellano, D.
Gurney, H.
Donskov, F.
Bono, P.
Wagstaff, J.
Gauler, T. C.
Ueda, T.
Xu, L. A.
Waxman, I. M.
Motzer, R. J.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S708
[43] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC)
Gruellich, C.
Powles, T.
Motzer, R. J.
George, D. J.
Jonasch, E.
Pal, S. K.
Tannir, N. M.
Signoretti, S.
Mai, T. H.
Scheffold, C.
Wang, E.
Aftab, D. T.
Escudier, B. J.
Choueiri, T. K.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 201 - 201
[44] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
Powles, T.
Motzer, R. J.
George, D. J.
Jonasch, E.
Pal, S.
Tannir, N. M.
Signoretti, S.
Mai, T. H.
Scheffold, C.
Wang, E.
Aftab, D. T.
Escudier, B.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2017, 28
[45] Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study
Escudier, Bernard J.
Powles, Thomas
Motzer, Robert J.
Olencki, Thomas
Aren, Osvaldo Rudy
Oudard, Stephane
Bracarda, Sergio
Tomczak, Piotr
Castellano, Daniel E.
Appleman, Leonard Joseph
Drabkin, Harry A.
Vaena, Daniel A.
Milwee, Steven
Youkstetter, Jillian
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[46] Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Choueiri, Toni K.
McDermott, David F.
Merchan, Jaime
Bauer, Todd M.
Figlin, Robert
Heath, Elisabeth, I
Michaelson, M. Dror
Arrowsmith, Edward
D'Souza, Anishka
Zhao, Song
Roy, Ananya
Perini, Rodolfo
Vickery, Donna
Tykodi, Scott S.
LANCET ONCOLOGY, 2023, 24 (05): : 553 - 562
[47] Patients' self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study
Hong, Sung-Hoo
Chung, Ho Seok
Seo, Ill-Young
Kwon, Tae Gyun
Jeong, Hyeon
Chung, Jae-Il
Jeon, Seung Hyun
Park, Jae Young
Ha, Hong Koo
Chung, Byung-Ha
Song, Wan
Kim, Young-Joo
Kim, Sang-Hee
Lee, Jee-Sun
Lee, Juneyoung
Chung, Jinsoo
JOURNAL OF PATIENT-REPORTED OUTCOMES, 2022, 6 (01)
[48] Patients’ self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study
Sung-Hoo Hong
Ho Seok Chung
Ill-Young Seo
Tae Gyun Kwon
Hyeon Jeong
Jae-Il Chung
Seung Hyun Jeon
Jae Young Park
Hong Koo Ha
Byung-Ha Chung
Wan Song
Young-Joo Kim
Sang-Hee Kim
Jee-Sun Lee
Juneyoung Lee
Jinsoo Chung
Journal of Patient-Reported Outcomes, 6
[49] CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Escudier, Bernard
Sharma, Padmanee
McDermott, David F.
George, Saby
Hammers, Hans J.
Srinivas, Sandhya
Tykodi, Scott S.
Sosman, Jeffrey A.
Procopio, Giuseppe
Plimack, Elizabeth R.
Castellano, Daniel
Gurney, Howard
Donskov, Frede
Peltola, Katriina
Wagstaff, John
Gauler, Thomas C.
Ueda, Takeshi
Zhao, Huanyu
Waxman, Ian M.
Motzer, Robert J.
EUROPEAN UROLOGY, 2017, 72 (06) : 962 - 971
[50] Analysis of overall survival (OS) based on early tumour shrinkage in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
Tan, T. H.
Duran, I.
Maroto, P.
Suarez, C.
Castellano, D.
Garcia del Muro, X.
Costa, L.
Martin-Couce, L.
Benzaghou, F.
Thomas, S.
Markby, D. W.
Choueiri, T. K.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 186 - 186

← 1 2 3 4 5 →